J. Howard, S. Rakhade, J. Scholz, S. Ortiz, S. Shang, T. Vu
{"title":"PREVAIL试验的研究设计和方法:一项3期、随机、双盲、安慰剂对照的研究,研究了成人广泛性重症肌无力患者皮下注射ALXN1720的安全性和有效性(P1-5.008)","authors":"J. Howard, S. Rakhade, J. Scholz, S. Ortiz, S. Shang, T. Vu","doi":"10.1212/wnl.0000000000202990","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":334567,"journal":{"name":"Sunday, April 23","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study design and methodology of the PREVAIL trial: a phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of subcutaneous ALXN1720 in adults with generalized myasthenia gravis (P1-5.008)\",\"authors\":\"J. Howard, S. Rakhade, J. Scholz, S. Ortiz, S. Shang, T. Vu\",\"doi\":\"10.1212/wnl.0000000000202990\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":334567,\"journal\":{\"name\":\"Sunday, April 23\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sunday, April 23\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1212/wnl.0000000000202990\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sunday, April 23","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/wnl.0000000000202990","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Study design and methodology of the PREVAIL trial: a phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of subcutaneous ALXN1720 in adults with generalized myasthenia gravis (P1-5.008)